Breaking News Instant updates and real-time market news.

AKBA

Akebia

$15.25

0.2 (1.33%)

, FGEN

FibroGen

$43.35

0.95 (2.24%)

16:30
12/18/17
12/18
16:30
12/18/17
16:30

Akebia initiated with an Overweight at Piper Jaffray

Piper Jaffray analyst Christopher Raymond initiated Akebia (AKBA) with an Overweight rating and a price target of $26. The analyst cites the company's "combination of sound biology, clean safety, meaningful unmet medical need and an attractive relative valuation". While the near term prospects for Akebia revolve around first-to- market player Fibrogen (FGEN) in the HIF space, the analyst contends, Akebia can generate its own share of anemia market once its lead compound vadadustat is approved.

AKBA

Akebia

$15.25

0.2 (1.33%)

FGEN

FibroGen

$43.35

0.95 (2.24%)

AKBA Akebia
$15.25

0.2 (1.33%)

12/07/17
12/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/17
BTIG
12/07/17
INITIATION
Target $30
BTIG
Buy
Akebia initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Akebia with a Buy rating and a price target of $30. Hazlett says the company's development of Vadadustat - an HIF-PH inhibitor for anemia secondary to chronic kidney disease - has the potential to attain "hemoglobin control with material advantages compared to current standard-of-care injectable erythropoiesis stimulating agents". With its development partnerships in Japan and EU, the treatment is in a Phase 3 program expected for readouts in the first half of 2019.
11/15/17
HCWC
11/15/17
NO CHANGE
Target $24
HCWC
Buy
Akebia recent selloff not based on fundamentals, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce notes that since the close on November 8, shares of FibroGen (FGEN) are down 17% while Akebia Therapeutics (AKBA) is down 21.3%. He attributes some of the weakness to FibroGen's Q3 earnings call, in which concerns arose that cardiovascular events in the large Phase 3 roxadustat cardiovascular outcomes trials are accruing too slowly. The analyst believes this has no fundamental bearing on Akebia or vadadustat, however. He keeps a Buy rating on the shares with a $24 price target.
10/04/17
MZHO
10/04/17
INITIATION
MZHO
Buy
Akebia initiated with a Buy at Mizuho
FGEN FibroGen
$43.35

0.95 (2.24%)

10/04/17
MZHO
10/04/17
INITIATION
MZHO
Neutral
FibroGen initiated with a Neutral at Mizuho
08/14/17
JEFF
08/14/17
NO CHANGE
JEFF
Buy
Expert IPF call positive for FibroGen, says Jefferies
Jefferies analyst Michael Yee says his call with two idiopathic pulmonary fibrosis experts was net positive for FibroGen (FGEN). Based on the available data, the experts estimated a 30%-40%-plus probability of success in Phase 3 for the company. The experts were "more conservative in the interpretation" of the data reported by Galapagos NV (GLPG), Yee tells investors in a research note. He reiterates a Buy rating on FibroGen given the "underappreciated value" for FG-3019 in IPF.
08/08/17
LEER
08/08/17
NO CHANGE
Target $82
LEER
Outperform
FibroGen price target raised to $82 from $52 at Leerink
Leerink analyst Geoffrey Porges raised his price target for FibroGen to $82 from $52 after the company reported Q2 results and disclosed positive top-line results for the first phase of the ongoing phase II trial of pamrevlumab in idiopathic pulmonary fibrosis. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Housing Market Index to be reported at 10:00 »

July Housing Market Index…

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Breaking General news story  »

Federal Reserve Chairman…

CMCSA

Comcast

$34.98

(0.00%)

, CMCSK

Comcast

$0.00

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Periodicals
NBCU relaunches Craftsy as subscription-video service Bluprint, Variety reports »

NBCUniversal Cable…

CMCSA

Comcast

$34.98

(0.00%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$124.70

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Hot Stocks
Johnson & Johnson says 'disappointed' in Spine & Knee medical sales results »

Says Spine still an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

BA

Boeing

$356.01

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Hot Stocks
Boeing, Xiamen Airlines announce optimized maintenance program deal »

Boeing and Xiamen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SNA

Snap-On

$163.93

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Recommendations
Snap-On analyst commentary  »

Snap-On checks point to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 16

    Aug

VEON

Veon

$3.05

(0.00%)

, HFC

HollyFrontier

$68.91

(0.00%)

09:40
07/17/18
07/17
09:40
07/17/18
09:40
Options
Unusually active option classes on open July 17th »

Unusual total active…

VEON

Veon

$3.05

(0.00%)

HFC

HollyFrontier

$68.91

(0.00%)

DUST

Direxion Daily Gold Miners Bear 3X ETF

$25.49

(0.00%)

UNH

UnitedHealth

$257.03

(0.00%)

JNJ

Johnson & Johnson

$124.70

(0.00%)

CZR

Caesars

$11.63

(0.00%)

GS

Goldman Sachs

$231.01

(0.00%)

MCD

McDonald's

$158.76

(0.00%)

ATVI

Activision Blizzard

$80.23

(0.00%)

GDX

Market Vector Gold Miners

$21.88

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

09:38
07/17/18
07/17
09:38
07/17/18
09:38
Recommendations
Netflix analyst commentary  »

Netflix Q2 weakness is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$194.01

-2 (-1.02%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Initiation
Wex initiated  »

Wex initiated with a Peer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Periodicals
Lloyd Blankfein writes farewell memo to Goldman Sachs team, NY Times reports »

Goldman Sachs CEO LLoyd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$58.79

1.04 (1.80%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Recommendations
Nevro analyst commentary  »

Nevro price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

FLT

FleetCor

$216.11

-4.06 (-1.84%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FleetCor initiated  »

FleetCor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$66.95

-0.06 (-0.09%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
Square initiated  »

Square initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

FIS

FIS

$107.72

-0.45 (-0.42%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FIS initiated  »

FIS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

09:35
07/17/18
07/17
09:35
07/17/18
09:35
General news
Treasury Action: yields traded mixed-to-lower with stocks »

Treasury Action: yields…

EPAM

Epam Systems

$132.28

-1.3 (-0.97%)

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 15

    Aug

  • 16

    Aug

PAYX

Paychex

$69.99

-0.57 (-0.81%)

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Paychex initiated  »

Paychex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISV

Fiserv

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Fiserv initiated  »

Fiserv initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CLGX

CoreLogic

$53.31

0.04 (0.08%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
CoreLogic initiated  »

CoreLogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
Alliance Data initiated  »

Alliance Data initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

WU

Western Union

$20.27

-0.09 (-0.44%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
Western Union initiated  »

Western Union initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$137.13

-0.19 (-0.14%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
ADP initiated  »

ADP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

DXC

DXC Technology

$85.74

-0.41 (-0.48%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
DXC Technology initiated  »

DXC Technology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$167.63

-0.48 (-0.29%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$63.96

-0.74 (-1.14%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Technical Analysis
Technical Earnings Preview: CSX may have double-topped before news »

On the 1-year, daily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.